A Strategic Analysis of the Global Anti-obesity Prescription Pharmaceuticals Market

Regular Price: USD 3,950.00

Special Price USD 3,555.00

10% OFF

* Required Fields

Regular Price: USD 3,950.00

Special Price USD 3,555.00


Be the first to review this product

Prescription drug therapy for the treatment of obesity is experiencing a revival of interest with new government incentives and the recent approval of 2 new drugs, with 2 more pending imminent approval. This research service focuses on the competitive landscape of prescription drugs for the treatment of obesity. A global product and pipeline assessment is provided for marketed and investigational products. Segmentation by drug class is provided along with additional supporting information, such as clinical-trial timelines and results, historical and projected launch timelines, regulatory guidelines for clinical trial design and approval, and global epidemiology by region.

Table of Contents

Executive SummaryMarket Developments Since Q1 2013Executive SummaryExecutive Summary (continued)Drug Discovery PartnershipsDrug Discovery Partnerships (continued)Companies to WatchMethodology and ScopeMethodology and ScopeIntroduction to the Global Anti-obesity Prescription Drugs MarketObesity Indication BackgroundObesity Indication Background (continued)Obesity Indication Background (continued)Historical and Projected Timeline for Anti-obesity DrugsPotential Prescribing Behavior ScenarioRegulators’ Recommendations for Designing Anti-obesity Drug Clinical TrialsRegional Comparison of Drug Approval RequirementsGlobal Prevalence of Obesity by RegionGlobal Prevalence of Obesity by Region (continued)Market Overview—SegmentationCompetitive LandscapeAnti-obesity Prescription Pharmaceuticals Market—Competitive LandscapeOngoing Phase 3 Trials for Obesity DrugsOngoing Post-marketing Trials for Obesity DrugsComparative Efficacy of Obesity DrugsComparative Efficacy of Obesity Drugs (continued)Pivotal Trial Programs of Recently Approved Anti-obesity DrugsPivotal Trial Programs of Late-stage Anti-obesity DrugsPivotal Trial Programs of Late-stage Anti-obesity Drugs (continued)Marketed Products SynopsisMarketed Products Synopsis (continued)Marketed Products Synopsis (continued)Pipeline SynopsisPipeline Synopsis (continued)Pipeline Synopsis (continued)Pipeline Synopsis (continued)Pipeline Synopsis (continued)Pipeline Synopsis (continued)Product Dashboard—Qsymia (phentermine/topiramat ER)Product Dashboard—Belviq (lorcaserin HCl)Product Dashboard—Contrave (bupropion SR/ naltrexone SR)Product Dashboard—Victoza (liraglutide)Conclusions and RecommendationsConclusions and RecommendationsConclusions and Recommendations (continued)Legal DisclaimerAppendixDecision Support Database—Global Prevalence of ObesityDecision Support Database—Global Prevalence of Obesity (continued)Decision Support Database—Global Prevalence of Obesity (continued)Decision Support Database—Global Prevalence of Obesity (continued)List of ReferencesThe Frost & Sullivan StoryThe Frost & Sullivan StoryValue PropositionGlobal PerspectiveIndustry Convergence360º Research PerspectiveImplementation ExcellenceOur Blue Ocean Strategy

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.